Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika BrzezinskaLinda J. WilliamsJ. Michael Dixon Editorial 18 October 2016 Pages: 387 - 391
Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care Rossella GraffeoLuca LivraghiJudy E. Garber Review 12 October 2016 Pages: 393 - 410
Circulating tumor cells in breast cancer: applications in personalized medicine Jin Sun LeeMark Jesus M. MagbanuaJohn W. Park Review 19 October 2016 Pages: 411 - 424
Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials Fausto PetrelliSandro BarniSerena Di Cosimo Review 21 October 2016 Pages: 425 - 437
miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients András LánczkyÁdám NagyBalázs Győrffy Preclinical study 15 October 2016 Pages: 439 - 446
Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family Ciyu YangAngela G. ArnoldLiying Zhang Preclinical study 18 October 2016 Pages: 447 - 456
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer Feixiong ChengJunfei ZhaoZhongming Zhao Preclinical study 22 October 2016 Pages: 457 - 474
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems Misun ChoiYeon Hee ParkEun Yoon Cho Clinical trial 11 October 2016 Pages: 475 - 489
Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade A. HennigsF. RiedelA. Schneeweiss Clinical Trial Open access 15 October 2016 Pages: 491 - 499
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study M. E. CazzanigaL. CortesiOn behalf of VICTOR Study Group Clinical trial Open access 17 October 2016 Pages: 501 - 509
Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients M. C. van MaarenL. de MunckL. J. A. Strobbe Epidemiology 11 October 2016 Pages: 511 - 521
Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors Hyejin CheonHye Jung KimWon Hwa Kim Epidemiology 17 October 2016 Pages: 523 - 530
Investigation of breast cancer sub-populations in black and white women in South Africa Caroline DickensRuth M. PfeifferValerie A. McCormack Epidemiology 18 October 2016 Pages: 531 - 537
Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study Marian L. NeuhouserAshley Wilder SmithRachel Ballard Epidemiology 21 October 2016 Pages: 539 - 546
Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk Mara A. SchonbergVicky W. LiLong H. Ngo Epidemiology 21 October 2016 Pages: 547 - 562
Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race Chinwe C. MadubataYing LiuGraham A. Colditz Epidemiology 22 October 2016 Pages: 563 - 572
Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient Thomas M. ChurillaBrian L. EglestonRichard J. Bleicher Erratum 20 October 2016 Pages: 573 - 573
